The DOI matches its Crossref record.
Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study
Open accessAbstract
Objective.: To evaluate the frequency, timing, and clinical features of relapses in giant cell arteritis (GCA). Methods.: Patients with GCA enrolled in a prospective, multicenter, longitudinal study were included in the analysis. Relapse was defined as either new disease activity after a period of remission or worsening disease activity. Results.: The study included 128 subjects: 102 women (80%) and 26 men (20%). Mean ± SD age at diagnosis of GCA was 69.9 ± 8.6 years. Mean followup for the cohort was 21.4 ± 13.9 months. Median (interquartile range) duration of disease at study enrollment was 4.6 months (1.2, 16.8). During followup, 59 relapses were observed in 44 patients (34%). Ten patients (8%) experienced 2 or more relapses. The most common symptoms at relapse were headache (42%) and polymyalgia rheumatica (51%), but ischemic (some transient) manifestations (visual symptoms, tongue or jaw claudication, and/or limb claudication) occurred in 29% of relapses (12% cohort). Forty-three relapses (73%) occurred while patients were taking glucocorticoid therapy at a median (range) prednisone dose of 7.5 (0–35) mg. In 21% of relapses, both erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were normal. Among 69 patients enrolled in the cohort with newly diagnosed disease, 24% experienced a first relapse within 12 months after diagnosis. Conclusion.: Among patients with GCA, relapses are common, often occurring during treatment. ESR and CRP are frequently normal at times of clinical relapse, highlighting the need for better biomarkers to assess disease activity in GCA. There remains a need for effective therapeutic alternatives to glucocorticoids in GCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215672 · Cited by 1,200
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
Langford, C. A., Cuthbertson, D., Ytterberg, S. R., Khalidi, N., Monach, P. A., Carette, S., Seo, P., Moreland, L. W., Weisman, M., Koening, C. L., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40044 · Cited by 394
Self-citationDejaco, C., Duftner, C., Buttgereit, F., Matteson, E. L., & Dasgupta, B. (2016) · Rheumatology · doi:10.1093/rheumatology/kew273 · Cited by 365
Metadata
- Authors
- Kermani, T. A., Warrington, K. J., Cuthbertson, D., Carette, S., Hoffman, G. S., Khalidi, N. A., Koening, C. L., Langford, C. A., Maksimowicz-McKinnon, K., McAlear, C. A., Monach, P. A., Seo, P., Merkel, P. A., & Ytterberg, S. R.
- Venue
- The Journal of Rheumatology
- Publisher
- The Journal of Rheumatology
- Published
- 2015-04-15
- Volume
- 42
- Issue
- 7
- Pages
- 1213-1217
- ISSN
- 0315-162X (ISSN-L)
- 1499-2752
- OpenAlex
- W2321155811
- Cited by
- 185
- References
- 0
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. https://app.cochat.ai/papers/10.3899/jrheum.141347
- The paper
- Kermani, T. A., Warrington, K. J., Cuthbertson, D., Carette, S., Hoffman, G. S., Khalidi, N. A., Koening, C. L., Langford, C. A., Maksimowicz-McKinnon, K., McAlear, C. A., Monach, P. A., Seo, P., Merkel, P. A., & Ytterberg, S. R. (2015). Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. The Journal of Rheumatology. https://doi.org/10.3899/jrheum.141347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.